The variants more frequently observed were: KRAS c.35G>A (p.G12D) and c.35G>T (p.G12V), but also MET c.504G>T (p.E168D) in GI tumors; TP53 c.742C>T (p.R248W) in hematologic malignancies; KRAS c.34G>T (p.G12C) and c.35G>T (p.G12V) in lung; PIK3CA c.3140A>G (p.H1047R) and c.3140A>T (p.H1047L) in breast and BRAF c.1799T>A (p.V600E) in both melanoma and head and neck cancers (Table S5). Here, MET is linked to hematologic disorder.